Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

@article{Dooley2011MycophenolateVA,
  title={Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.},
  author={Mary Anne Dooley and David R. W. Jayne and Ellen M Ginzler and David A. Isenberg and Nancy J Olsen and David Wofsy and Frank Eitner and Gerald B. Appel and Gabriel N. Contreras and Laura J Lisk and Neil B. Solomons},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 20},
  pages={
          1886-95
        }
}
BACKGROUND Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and prevent relapse after the initial control of lupus nephritis. METHODS We carried out a 36-month, randomized, double-blind, double-dummy, phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per kilogram of body weight per day), plus placebo in each group, in patients who met response criteria during a 6-month induction trial. The… Expand
Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis
TLDR
Maintenance therapy with MMF was shown to yield favorable outcome with minimal complications, in treating lupus nephritis (IRCT2012071710313N1), and the effect of treatment on parameters over time was assessed. Expand
Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up
TLDR
All treatments had similar efficacy in achieving and maintaining CRR, despite more severe baseline clinical features in patients treated with CsA, MMF and AZA on long-term LN maintenance therapy. Expand
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up
TLDR
TAC is non-inferior to MMF, when combined with prednisolone, for induction therapy of active LN, and with azathioprine maintenance for 5 years, a non-significant trend of higher incidence of renal flares and renal function decline is observed with the TAC regimen. Expand
Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study
TLDR
For induction phase treatment, Nepalese patients with lupus nephritis responded favorably to steroid and low dose IVC of 3 grams given as six monthly pulses. Expand
Mycophenolate as Maintenance Therapy for Lupus Nephritis with Impaired Renal Function
TLDR
Mycophenolate is effective and safe as a maintenance therapy for LN both in patients with normal renal function and in those with renal impairment. Expand
Multitarget Therapy for Maintenance Treatment of Lupus Nephritis.
TLDR
Multitarget therapy as a maintenance treatment for lupus nephritis resulted in a low renal relapse rate and fewer adverse events, suggesting that multitarget therapy is an effective and safe maintenance therapy for patients with lupu nephitis. Expand
Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial
TLDR
EC-MPS was superior to AZA in treating SLE and preventing further relapses and AEs were similar in both groups except for leucopenia that occurred more frequently with AZA. Expand
The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis
TLDR
Bortezomib combined with glucocorticoids reduces proteinuria, improves renal function and decreases anti-autoantibodies, with good tolerance and mild adverse events, thus representing an alternative therapy for refractory LN and warranting further study. Expand
The Mycophenolate Mofetil Therapy in Corticoresistent Idiopathic Focal Segmental Glomerulosclerosis
TLDR
It was concluded that in resistant Nephrotic Syndrome by FSGS, MMF can favor stable remission, preserving renal function and hence being considered as an alternative therapy to calcineurin inhibitors, but with lower toxicity. Expand
Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil
TLDR
Long-term outcomes in terms of patient and renal survival of LN patients treated with CYP and MMF induction are similar, and most deaths occurred during induction, and sepsis was the most common cause of death. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
TLDR
Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis. Expand
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
TLDR
In this 24-week randomized, open-label, noninferiority trial, mycophenolate mofetil was more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis and had a more favorable safety profile. Expand
Mycophenolate Mofetil versus Azathioprine in the Maintenance Therapy of Lupus Nephritis
TLDR
Both therapeutic approaches with MMF or AZA, in combination with corticosteroids, are effective as a maintenance therapy for lupus nephritis. Expand
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
TLDR
Fewer renal flares were observed in patients receiving MMF but the difference did not reach statistical significance and over a 3-year period, 24 h proteinuria, serum creatinine, serum albumin, serum C3, haemoglobin and global disease activity scores improved similarly in both groups. Expand
Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)
TLDR
The Phase III Aspreva Lupus Management Study (ALMS) may provide invaluable comparative data on the efficacy and safety of MMF as LN induction and maintenance therapy. Expand
Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
TLDR
It is concluded that MMF and prednisolone constitute an effective continuous induction-maintenance treatment for DPLN in Chinese patients. Expand
Induction and maintenance therapy in proliferative lupus nephritis.
TLDR
Modern immunosuppression today allows us to reduce the dosage of steroids and to avoid the prolonged use of cyclophosphamide, and these newer strategies may result in fewer adverse effects, better quality of life and better survival for patients with proliferative lupus nephritis. Expand
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
TLDR
Mycophenolate mofetil is a suitable alternative to cyclophosphamide for the treatment of renal and nonrenal disease manifestations in patients with biopsy-proven lupus nephritis and showed that remission could also be induced in other systems. Expand
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
TLDR
For the treatment of diffuse proliferative lupus nephritis, the combination of mycophenolate mofetil and prednisolone is as effective as a regimen of cyclophosphamide and prednesolone followed by azathioprine and predisonsolone but is less toxic. Expand
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
TLDR
MMF and IVC have similar efficacy overall to short-term induction therapy for LN, however, race, ethnicity and geographical region may affect treatment response; more Black and Hispanic patients responded to MMF than IVC. Expand
...
1
2
3
...